Everolimus-based Calcineurin-inhibitor Sparing Regimens for Kidney Transplant Recipients: a Systematic Review and Meta-analysis

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2014 Jul 17

PMID 25027805

Citations 14

Authors

Liya Su

Ngalei Tam

Ronghai Deng

Philip Chen

Haibo Li

Linwei Wu

Affiliations

Soon will be listed here.

Abstract

Purpose: Calcineurin inhibitors (CNI) associated nephrotoxicity remains a risk factor for long-term graft dysfunction after renal transplantation. Everolimus is a mammalian target of rapamycin inhibitor and exhibits synergistic immunosuppressive activity with CNI to permit CNI-reduction. We conducted a systematic review to compare the efficacy of everolimus-based CNI sparing and standard CNI regimens in renal transplantation recipients.

Methods: We searched PubMed and Web of Science databases to identify relevant randomized controlled trials. Glomerular filtration rate (GFR), biopsy-proven acute rejection (BPAR), death or graft loss and incidence of adverse events were the major estimates of renal function, efficacy, and tolerability of the two regimens.

Results: Seven studies providing data for 2,067 patients were included. Six of the seven studies used cyclosporine as the CNI. The patients were divided into two groups: everolimus-based CNI sparing (elimination and minimization) group and standard CNI group. Everolimus-based regimen was associated with increased GFR [P = 0.02; weighted mean difference (WMD) 4.83 mL/min], decreased serum creatinine (P = 0.004; WMD -9.94 μmol/L) and no more death or graft loss [P = 0.72; relative risk (RR) 1.07]. CNI-minimization was not associated with increased BPAR (P = 0.25; RR 0.85) while CNI-elimination was associated with more BPAR Grade 1 (P < 0.00001; RR 4.20). Use of everolimus reduced the risk of CMV infection (P = 0.0002; RR 0.47). There was a higher risk of discontinuation of everolimus (P < 0.00001; RR 1.69) and non-fatal adverse events (P < 0.00001; RR 1.73) in patients on the everolimus based CNI sparing regimens.

Conclusions: Everolimus-based CNI sparing regimen could optimize long-term graft function without leading to more death or graft loss. Although CNI elimination was associated with higher risk of BPAR, everolimus use with CNI minimization did not increase the risk of acute rejections. Use of everolimus was associated with reduction in the incidence of CMV infection, but there was a higher risk of discontinuation of this drug and other non-fatal adverse events.

Citing Articles

Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma.

Chen J, Li H, Zhuo J, Lin Z, Hu Z, He C Cancer Biol Med. 2024; 21(11.

PMID: 39718153 PMC: 11667780. DOI: 10.20892/j.issn.2095-3941.2024.0267.

Difficult-to-Treat Rejections in Kidney Transplant Recipients: Our Experience with Everolimus-Based Quadruple Maintenance Therapy.

Larsson P, Englund B, Ekberg J, Felldin M, Broecker V, Mjornstedt L J Clin Med. 2023; 12(20).

PMID: 37892805 PMC: 10607360. DOI: 10.3390/jcm12206667.

Risk Factors for Cytomegalovirus Infection and Its Impact on Survival after Living Donor Liver Transplantation in South Korea: A Nested Case-Control Study.

Yim S, Choi M, Kim D, Min E, Lee J, Joo D Pathogens. 2023; 12(4).

PMID: 37111407 PMC: 10143532. DOI: 10.3390/pathogens12040521.

Real-World Treatment Patterns of Antiviral Prophylaxis for Cytomegalovirus Among Adult Kidney Transplant Recipients: A Linked USRDS-Medicare Database Study.

Raval A, Ganz M, Fraeman K, Lorden A, Saravanan S, Tang Y Transpl Int. 2022; 35:10528.

PMID: 36046353 PMC: 9421942. DOI: 10.3389/ti.2022.10528.

Therapeutic drug level of tacrolimus causing intracranial hemorrhage in a patient with renal transplant.

Shah S, Ojha R, Chamlagain R, Chhetri S, Pravin Prasad , Baral B Clin Case Rep. 2022; 10(4):e05788.

PMID: 35498342 PMC: 9043708. DOI: 10.1002/ccr3.5788.

References

Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A . Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562-75. DOI: 10.1056/NEJMoa067411. View

Mahe E, Morelon E, Lechaton S, Le Quan Sang K, Mansouri R, Ducasse M . Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation. 2005; 79(4):476-82. DOI: 10.1097/01.tp.0000151630.25127.3a. View

Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U . Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011; 377(9768):837-47. DOI: 10.1016/S0140-6736(10)62318-5. View

Kaplan B, Qazi Y, Wellen J . Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando). 2014; 28(3):126-33. DOI: 10.1016/j.trre.2014.03.002. View

Groth C, Backman L, Morales J, Calne R, Kreis H, Lang P . Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999; 67(7):1036-42. DOI: 10.1097/00007890-199904150-00017. View

Asberg A, Midtvedt K, Line P, Narverud J, Holdaas H, Jenssen T . Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation. 2006; 82(1):62-8. DOI: 10.1097/01.tp.0000225803.04995.2b. View

Vitko S, Margreiter R, Weimar W, Dantal J, Viljoen H, Li Y . Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation. 2004; 78(10):1532-40. DOI: 10.1097/01.tp.0000141094.34903.54. View

Lv C, Chen M, Xu M, Xu G, Zhang Y, He S . Influencing factors of new-onset diabetes after a renal transplant and their effects on complications and survival rate. PLoS One. 2014; 9(6):e99406. PMC: 4050028. DOI: 10.1371/journal.pone.0099406. View

Calne R, White D, Thiru S, Evans D, McMaster P, Dunn D . Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978; 2(8104-5):1323-7. DOI: 10.1016/s0140-6736(78)91970-0. View

10.

Lutz J, Zou H, Liu S, Antus B, Heemann U . Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation. 2003; 76(3):508-15. DOI: 10.1097/01.TP.0000074722.79186.A9. View

11.

Sellares J, de Freitas D, Mengel M, Sis B, Hidalgo L, Matas A . Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am J Transplant. 2011; 11(3):489-99. DOI: 10.1111/j.1600-6143.2010.03415.x. View

12.

Helal I, Abderrahim E, Ben Hamida F, Ounissi M, Essine S, Hedri H . The first year renal function as a predictor of long-term graft survival after kidney transplantation. Transplant Proc. 2009; 41(2):648-50. DOI: 10.1016/j.transproceed.2009.02.036. View

13.

Holdaas H, Midtvedt K, Asberg A . A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf. 2012; 11(6):1013-22. DOI: 10.1517/14740338.2012.722993. View

14.

Eisen H . Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant. 2006; 21 Suppl 3:iii9-13. DOI: 10.1093/ndt/gfl295. View

15.

Watanabe R, Wei L, Huang J . mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med. 2011; 52(4):497-500. DOI: 10.2967/jnumed.111.089623. View

16.

Sagedal S, Nordal K, Hartmann A, Sund S, Scott H, Degre M . The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant. 2002; 2(9):850-6. DOI: 10.1034/j.1600-6143.2002.20907.x. View

17.

Flechner S, Glyda M, Cockfield S, Grinyo J, Legendre C, Russ G . The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant. 2011; 11(8):1633-44. DOI: 10.1111/j.1600-6143.2011.03573.x. View

18.

Salvadori M, Rosati A, Bock A, Chapman J, Dussol B, Fritsche L . Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. Transplantation. 2006; 81(2):202-6. DOI: 10.1097/01.tp.0000188135.04259.2e. View

19.

Resende L, Guerra J, Santana A, Mil-Homens C, Abreu F, da Costa A . First year renal function as a predictor of kidney allograft outcome. Transplant Proc. 2009; 41(3):846-8. DOI: 10.1016/j.transproceed.2009.01.066. View

20.

Schuurman H, Cottens S, Fuchs S, Joergensen J, Meerloo T, Sedrani R . SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation. 1997; 64(1):32-5. DOI: 10.1097/00007890-199707150-00007. View